F059 Women’s Health Therapeutic Hotline
DESCRIPTION
In this therapeutics symposium, we will discuss special considerations when caring for women with chronic inflammatory skin conditions such as psoriasis, atopic dermatitis, hidradenitis, and blistering disease. We review the role of contraception in the dermatology clinical encounter and safety information regarding biologics in pregnancy. We will also discuss diagnostic and therapeutic strategies for treatment of hair loss in women, with a special focus on how to ensure accurate diagnoses in our skin of color patients. This course is packed with clinical pearls for the practicing dermatologist.
LEARNING OBJECTIVES
Describe the key principles in contraception that all dermatologists should be aware of when making treatment recommendations to patients.
Determine the optimal therapeutic strategy for women with chronic inflammatory skin conditions such as psoriasis, atopic dermatitis and hidradenitis, with detailed information regarding the risk assessment of biologics in pregnancy.
Delineate special considerations when taking care of women with hair loss, emphasizing the differences in approach for hair curl index 1-2 and 3-4 patients.
SCHEDULE
1:00 PM
Introduction
Jenny Eileen Murase, MD, FAAD
1:05 PM
Hair loss in women - high vs. low curl index patient management
Valerie D. Callender, MD, FAAD
1:25 PM
Q&A
Valerie D. Callender, MD, FAAD
1:30 PM
Psoriasis in Women
Julia-Tatjana Maul, MD
1:45 PM
Q&A
Julia-Tatjana Maul, MD
1:55 PM
Hidradenitis in Women
Drew Kenith Saylor, MD, FAAD
2:10 PM
Q&A
Drew Kenith Saylor, MD, FAAD
2:15 PM
The Role of Contraception for the Dermatologist
Sheila Mody, MD
2:30 PM
Q&A
Sheila Mody, MD
2:35 PM
Biologics in Pregnancy
Jenny Eileen Murase, MD, FAAD
2:50 PM
Q&A
Jenny Eileen Murase, MD, FAAD
DIRECTOR
Jenny Eileen Murase, MD, FAAD
SPEAKERS
Valerie D. Callender, MD, FAAD
Julia-Tatjana Maul, MD
Sheila Mody, MD
Drew Kenith Saylor, MD, FAAD
HANDOUTS
DISCLOSURES
Valerie D. Callender, MD, FAAD
Aerolase – Advisory Board(Stock Options), Speaker/Faculty Education(Honoraria); Allergan, Inc – Investigator(Grants/Research Funding); Allergan, Inc. – Consultant(Honoraria); Arcutis Biotherapeutics – Speaker(Honoraria); AVAVA, LLC – Investigator(Grants/Research Funding); Beiersdorf, Inc. – Consultant(Honoraria); Cutera – Consultant(Honoraria), Speaker(Honoraria); Dermavant Sciences – Advisory Board(Honoraria); Eirion Therapeutics – Investigator(Grants/Research Funding); Eli Lilly – Speaker/Faculty Education(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); Erion – Investigator(Grants/Research Funding); Iknow Skincare – Investigator(Grants/Research Funding); janssen – Investigator(Grants/Research Funding); Juenes Aesthetics – Advisory Board(Honoraria); L'Oreal USA Inc. – Consultant(Honoraria), Investigator(Honoraria); La Roche-Posay - L'Oreal Group – Advisory Board(Honoraria); Ortho Dermatologics – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(No Compensation Received); Prollenium Medical Technologies – Investigator(Grants/Research Funding); Sente Labs – Advisory Board(Honoraria); SkinCeuticals LLC – Advisory Board(Honoraria), Speaker(Honoraria); symatese – Investigator(Grants/Research Funding); TEOXANE Laboratories – Investigator(Grants/Research Funding); UpToDate – Other(Patent royalties or other compensation for Intellectual Property Rights);
Julia-Tatjana Maul, MD
No financial relationships exist with ineligible companies.
Sheila Mody, MD
Bayer – Consultant (1099 relationship)(Honoraria); Organon & Co. – Investigator(Grants/Research Funding);
Jenny Eileen Murase, MD, FAAD
AbbVie – Consultant(Honoraria); Arcutis Biotherapeutics – Advisory Board(Honoraria); Bristol-Myers Squibb – Advisory Board(Honoraria); Galderma – Speaker(Honoraria); Regeneron – Speaker/Faculty Education(Honoraria); Sanofi – Speaker(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria); UCB – Consultant(Honoraria), Speaker/Faculty Education(Honoraria); UpToDate – Consultant(Honoraria);
Drew Kenith Saylor, MD, FAAD
No financial relationships exist with ineligible companies.